Y Intercept Hong Kong Ltd acquired a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 29,749 shares of the biotechnology company's stock, valued at approximately $510,000.
Several other hedge funds have also recently added to or reduced their stakes in the business. Hollencrest Capital Management acquired a new position in shares of ADMA Biologics during the third quarter worth approximately $30,000. Larson Financial Group LLC acquired a new position in ADMA Biologics during the 3rd quarter valued at $31,000. GAMMA Investing LLC raised its stake in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 967 shares during the last quarter. National Bank of Canada FI bought a new stake in ADMA Biologics in the 3rd quarter valued at $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics in the 3rd quarter worth $62,000. Institutional investors own 75.68% of the company's stock.
ADMA Biologics Price Performance
Shares of ADMA Biologics stock traded up $0.67 during trading on Wednesday, hitting $17.68. 4,507,779 shares of the company's stock traded hands, compared to its average volume of 3,361,794. The company has a market cap of $4.18 billion, a PE ratio of 63.14 and a beta of 0.75. The firm's fifty day moving average price is $16.69 and its 200 day moving average price is $17.97. ADMA Biologics, Inc. has a twelve month low of $5.71 and a twelve month high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.
Analyst Upgrades and Downgrades
ADMA has been the subject of several research reports. Raymond James increased their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a research note on Friday, November 8th. HC Wainwright upped their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday.
Read Our Latest Stock Report on ADMA
ADMA Biologics Company Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Stories
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
